Compare Gilead Sciences, Inc. (GILD) vs Lennar Corporation (LEN) Price & Performance

Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).

Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.

Lennar (LEN) trades at $76.13, down 1.65% on the day, with technical indicators showing bearish momentum. The stock trades below book value (P/B 0.84) and at a discount to peers (P/E 14.42), but faces headwinds from declining revenue and net income margins. Recent news highlights Berkshire Hathaway's growing stake (now 11.2% as of Sept 30, 2026) while Morgan Stanley issued a sell rating, reflecting divergent views on the housing recovery timeline.

The outlook remains challenged by high mortgage rates and weak builder sentiment, though Berkshire's accumulation suggests long-term value. Key risks include the Hunterbrook short report alleging questionable transactions and ongoing margin pressure. With earnings missing estimates for three consecutive quarters and Q3 guidance cut, near-term catalysts appear limited despite attractive valuation metrics.